Differentiating Low-Molecular-Weight Heparins Based on Chemical, Biological, and Pharmacologic Properties: Implications for the Development of Generic Versions of Low-Molecular-Weight Heparins

ABSTRACT

Low-molecular-weight heparins (LMWHs) are polypharmacologic drugs used to treat thrombotic and cardiovascular disorders. These drugs are manufactured using different chemical and enzymatic methods, resulting in products with distinct chemical and pharmacologic profiles. Generic LMWHs have been introduced in Asia and South America, and several generic suppliers are seeking regulatory approval in the United States and the European Union. For simple small-molecule drugs, generic drugs have the same chemical structure, potency, and bioavailability as the innovator drug. Applying this definition to complex biological products such as the LMWHs has proved difficult. One major issue is defining appropriate criteria to demonstrate bioequivalence; pharmacopoeial specifications alone appear to be inadequate. Whereas available generic versions of LMWHs exhibit similar molecular and pharmacopoeial profiles, marked differences in their biological and pharmacologic behavior have been noted. Preliminary studies have demonstrated differences in terms of anti-Xa activity and tissue factor pathway inhibitor release after subcutaneous administration, as well as antiplatelet and profibrinolytic effects. The current data emphasize the need to consider multiple functional parameters when defining bioequivalence of biologic drugs with complex structures and activities and also underscore the importance of further pharmacologic studies involving animal models and human clinical trials. The U.S. Food and Drug Administration and the European Medicine Evaluation Agency are currently developing guidelines for the acceptance of biosimilar agents including LMWHs. Until such guidelines are complete, generic interchange may not be feasible.

generic - low-molecular-weight heparin - pharmacodynamic

REFERENCES

• 1 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin.  Chest. 2004;  126 188S-203S
• 2 Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.  Semin Thromb Hemost. 2001;  27 503-511
• 3 Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.  Biochem J. 1981;  193 395-400
• 4 Khorana A A, Sahni A, Altland O D et al.. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight.  Arterioscler Thromb Vasc Biol. 2003;  23 2110-2115
• 5 Bray B, Lane D A, Freyssinet J M et al.. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.  Biochem J. 1989;  262 225-232
• 6 Jeske W P, Walenga J M, Fareed J. Differentiating between the low molecular-weight heparins used for venous thromboembolism treatment and prophylaxis.  Thrombosis Clin. 2008;  , in press
• 7 Casu B, Torri G. Structural characterization of low molecular weight heparins.  Semin Thromb Hemost. 1999;  25(Suppl 3) 17-25
• 8 Walenga J M, Petitou M, Samama M et al.. Importance of a 3-O-sulfate in a heparin pentasaccharide for antithrombotic activity.  Thromb Res. 1988;  52 553-563
• 9 Becker R C. New thrombolytic, anticoagulants and platelet antagonists: the future of clinical practice.  J Thromb Thrombolysis. 1999;  7 195-220
• 10 Antman E M, McCabe C H, Gurfinkel E P et al.. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial.  Circulation. 1999;  100 1593-1601
• 11 Cohen M, Demers C, Gurfinkel E P et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.  N Engl J Med. 1997;  337 447-452
• 12 Fareed J, Leong W L, Hoppensteadt D A et al.. Generic low-molecular-weight heparins: some practical considerations.  Semin Thromb Hemost. 2004;  30 703-713
• 13 Leong W, Hoppensteadt D A. Generic forms of low molecular weight heparins: some practical considerations.  Clin Appl Thromb Hemost. 2003;  9 293-297
• 14 U.S. Food and Drug Administration. 2003P-0064: Withhold approval of generic Lovenox (enoxaparin sodium injection). Available at: http://www.fda.gov/ohrms/dockets/DOCKETS/03p0064/03p0064.htm Accessed December 20, 2007
• 15 Linhardt R J, Gunay N S. Production and chemical processing of low molecular weight heparins.  Semin Thromb Hemost. 1999;  25(Suppl. 3) 5-16
• 16 Enoxaparin sodium.  Pharmacopeiac Forum. 2007;  33 52-57
• 17 Samama M M, Gerotziafas G T. Comparative pharmacokinetics of LMWHs.  Semin Thromb Hemost. 2000;  26(Suppl 1) 31-38
• 18 Collignon F, Frydman A, Caplain H et al.. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers.  Thromb Haemost. 1995;  73 630-640
• 19 Eriksson B I, Soderberg K, Widlund L et al.. A comparative study of three low-molecualr weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.  Thromb Haemost. 1995;  73 398-401
• 20 Criteria and evidence to assess actual or potential bioequivalence problems. Volume 21 CFR 320. 33: Federal Register 1998
• 21 Linhardt R J, Capila I. Heparin-protein interactions.  Angew Chem Int. 2002;  41 390-412
• 22 Lindahl U, Backstrom G, Thunberg L et al.. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.  Proc Natl Acad Sci U S A. 1980;  77 6551-6555
• 23 Petitou M, Lormeau J C, Choay J. Interaction of heparin and antithrombin III. The role of O-sulfate groups.  Eur J Biochem. 1988;  176 637-640
• 24 Nugent M A. Heparin sequencing brings structure to the function of complex oligosaccharides.  Proc Natl Acad Sci U S A. 2000;  97 10301-10303
• 25 Ahsan A, Jeske W, Hoppensteadt D et al.. Molecular profiling and weight determination of heparins and depolymerized heparins.  J Pharm Sci. 1995;  84 724-727
• 26 Ahsan A, Jeske W, Mardiguian J et al.. Feasability study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins.  J Pharm Sci. 1994;  83 197-201
• 27 Linhardt R J, Galliher P M, Cooney C L. Polysaccharide lyases.  Appl Biochem Biotechnol. 1986;  12 135-176
• 28 Jeske W P, Neville B, Ma Q et al.. Effect of 1,6-anhdro bicyclic ring structure on the pharmacokinetic and pharmacodynamic behavior of low molecular weight heparin.  Blood. 2004;  104 , abstract 1868
• 29 Jeske W, Fareed J. Antithrombin III and heparin cofactor II mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.  Semin Thromb Hemost. 1993;  19(suppl 1) 241-247
• 30 Ahmad S, Jeske W P, Ma Q et al.. Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.  Thromb Res. 2001;  102 143-151
• 31 Hoppensteadt D A, Jeske W P, Walenga J M et al.. Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.  Thromb Res. 1999;  96 115-124
• 32 Heparin sodium. United States Pharmacopeia. 29th Revision. Rockville, MD; The US Pharmacopeial Convention 2006
• 33 Jeske W P, Walenga J M, Ackerman P D et al.. Assay dependent variations in the anticoagulant and protamine sulfate neutralization profiles of generic copies of enoxaparin.  Blood. 2006;  108 272a
• 34 Frank R G. The ongoing regulation of generic drugs.  N Engl J Med. 2007;  357 1993-1996
• 35 Fareed J, Walenga J M, Hoppensteadt D A et al.. Immunogenic potential of generic versions of LMWHSs may not be the same as the branded products. http://Available at: www.natfonline.org/november_2007/etrhombosis_nov2007.html Accessed December 23, 2007